These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 24290218

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Update on therapeutic options in Waldenström macroglobulinemia.
    Leleu X, Gay J, Roccaro AM, Moreau AS, Poulain S, Dulery R, Champs BB, Robu D, Ghobrial IM.
    Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
    [Abstract] [Full Text] [Related]

  • 23. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
    Ghafoor B, Masthan SS, Hameed M, Akhtar HH, Khalid A, Ghafoor S, Allah HM, Arshad MM, Iqbal I, Iftikhar A, Husnain M, Anwer F.
    Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
    [Abstract] [Full Text] [Related]

  • 24. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
    Amaador K, Kersten MJ, Minnema MC, Vos JMI.
    Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
    [Abstract] [Full Text] [Related]

  • 25. Novel agents in Waldenström macroglobulinemia.
    Issa GC, Ghobrial IM, Roccaro AM.
    Clin Investig (Lond); 2011 Jan; 1(6):815-824. PubMed ID: 22034589
    [Abstract] [Full Text] [Related]

  • 26. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
    García-Sanz R, Tedeschi A.
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
    [Abstract] [Full Text] [Related]

  • 27. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S, Abeykoon JP, Kapoor P.
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [Abstract] [Full Text] [Related]

  • 28. Waldenström macroglobulinemia: What a hematologist needs to know.
    Kapoor P, Paludo J, Vallumsetla N, Greipp PR.
    Blood Rev; 2015 Sep; 29(5):301-19. PubMed ID: 25882617
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA, Chen C, Kastritis E, Gavriatopoulou M, Treon SP.
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
    Jalali S, Ansell SM.
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.
    Kristinsson SY, Goldin LR, Turesson I, Björkholm M, Landgren O.
    Acta Haematol; 2012 Jun; 127(3):173-7. PubMed ID: 22310551
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P, Paludo J, Ansell SM.
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [Abstract] [Full Text] [Related]

  • 38. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN, Miranda RN, Powell PR, Parekh PK.
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [Abstract] [Full Text] [Related]

  • 39. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis.
    Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM.
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):109-11. PubMed ID: 21454206
    [Abstract] [Full Text] [Related]

  • 40. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.
    Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP.
    Blood; 2009 Jan 15; 113(3):626-34. PubMed ID: 18981296
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.